SELLAS Life Sciences reported on Nov. 17 that its Phase III REGAL trial of galinpepimut-S (GPS), an investigational WT1-targeted cancer vaccine, met its primary endpoint in certain patients with relapsed acute myeloid leukemia (AML).
In the 126-patient trial, median overall survival was 24.0 months with GPS versus 14.7 months with investigator-selected best available treatment. The company reported a hazard ratio of 0.59—a 41% lower risk of death—and a two-sided p-value of 0.035.
The study involved patients in a second or later remission who were not eligible for a stem-cell transplant. GPS was generally well tolerated; reported treatment-related effects were mostly mild to moderate, especially injection-site reactions.
The result is an encouraging signal for cancer vaccines, particularly as maintenance treatment when cancer burden is lower. It is not proof that vaccines will work broadly across cancers:
this was one trial, in a specific AML population, and detailed results have not yet been presented in a peer-reviewed publication.
SELLAS says it plans to discuss an accelerated filing strategy with the FDA and is preparing for a possible Biologics License Application submission in the first half of 2027. The results are preliminary topline data, and regulatory approval is not assured.
Sources:
sec-gov-archives-edgar-data-1390478-000110465926128825-tm2629947d1-ex99-1-htm
sec-gov-archives-edgar-data-1390478-000110465926128825-tm2629947d1-8k-htm
Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
Sellas' AML win strengthens case for cancer vaccines in recurrence ...
SELLAS Cancer Vaccine Improves Overall Survival in Phase 3 AML Trial
SELLAS Reports Positive Phase 3 Cancer Vaccine Trial Results
SELLAS cancer vaccine cuts death risk 41% in Phase III AML trial, targets ...
Sellas Life Sciences Reports Positive Results From Trial for Cancer Vaccine
Experimental Blood Cancer Vaccine Improves Survival
Sellas Life Sciences Says Cancer Vaccine Meets Primary Endpoint in Phase 3 Trial
Sellas' cancer vaccine slashes death risk by 41% in late-stage AML study
Leukemia vaccine passes key trial, adding to breakthrough year for cancer drugs
Sellas stock surges on ‘conversation-changing’ Phase III cancer vaccine victory
Sellas stock surges on ‘conversation-changing’ Phase III cancer vaccine victory